Literature DB >> 12927670

Stent therapy for malignant superior vena cava syndrome: should be first line therapy or simple adjunct to radiotherapy.

A Chatziioannou1, Th Alexopoulos, D Mourikis, K Dardoufas, K Katsenis, S Lazarou, V Koutoulidis, Ch Ladopoulos, L Vlachos.   

Abstract

UNLABELLED: The goal of this paper is to present our experience with superior vena cava (SVC) stenting, as first line procedure for immediate relief, in patients with malignancy, and its potential influence in the subsequent radiotherapy (XRT). Over a 1-year period, 18 patients with SVC syndrome due to severe stenosis secondary to mediastinal malignancy were referred for stent insertion. A SVC score was used to measure treatment effectiveness. Stent insertion had been successful in 18/18 patients (technical success 100%). All patients experienced symptomatic relief within few hours of the procedure. There were no major complications. In all patients we were able to start radiotherapy (XRT) the next day, after stenting according to our new institutional protocol. All patients were able to comply with the XRT program, perfectly well.
CONCLUSIONS: SVC stenting provides immediate significant relief of the very annoying SVC syndrome symptoms, thus facilitating excellent compliance of all the patients to the subsequently XRT protocols. We strongly recommend SVC stenting as first line procedure, in patients with SVC syndrome due to malignancy prior to radiotherapy.

Entities:  

Mesh:

Year:  2003        PMID: 12927670     DOI: 10.1016/s0720-048x(02)00207-3

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  5 in total

1.  Pulseless Electrical Activity Arrest after SVC Dilation.

Authors:  Brian Funaki; Taral Doshi
Journal:  Semin Intervent Radiol       Date:  2007-12       Impact factor: 1.513

Review 2.  Palliative care in lung cancer.

Authors:  Betty Ferrell; Marianna Koczywas; Fred Grannis; Annie Harrington
Journal:  Surg Clin North Am       Date:  2011-04       Impact factor: 2.741

3.  A retrospective stenting study on superior vena cava syndrome caused by lung cancer.

Authors:  Sen Wei; Jinghao Liu; Xin Li; Zuoqing Song; Ming Dong; Honglin Zhao; Qingchun Zhao; Gang Chen; Jun Chen
Journal:  Thorac Cancer       Date:  2020-05-21       Impact factor: 3.500

Review 4.  Malignant Superior Vena Cava Syndrome: State of the Art.

Authors:  Vasileios Patriarcheas; Maria Grammoustianou; Nikolaos Ptohis; Ioanna Thanou; Minas Kostis; Ioannis Gkiozos; Andriani Charpidou; Ioannis Trontzas; Nikolaos Syrigos; Elias Kotteas; Evangelos Dimakakos
Journal:  Cureus       Date:  2022-01-04

Review 5.  Endovascular Stenting in Superior Vena Cava Syndrome: A Systematic Review and Meta-analysis.

Authors:  Eri Yin-Soe Aung; Maha Khan; Norman Williams; Usman Raja; Mohamad Hamady
Journal:  Cardiovasc Intervent Radiol       Date:  2022-07-12       Impact factor: 2.797

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.